Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 13/20 | 0.51 |
| ▸ | ACE | P12821 | 4/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18922305 | 1.00 | MME (0.51) | MMEACECTSSCTSKATM | |
| SCHEMBL15468114 | 0.92 | MME (0.58) | MMEACECTSSCTSKATM | |
| SCHEMBL20681853 | 0.92 | MME (0.58) | MMEACECTSSCTSKATM | |
| SCHEMBL18922306 | 0.90 | CTSS (0.48) | MMEACECTSSCTSKATM | |
| SCHEMBL19687929 | 0.90 | MME (0.53) | MMEACECTSL | |
| SCHEMBL18922308 | 0.90 | MME (0.53) | MMEACECTSL | |
| SCHEMBL19687828 | 0.88 | CTSS (0.49) | MMEACECTSSCTSKATM | |
| SCHEMBL15474327 | 0.88 | CTSS (0.49) | MMEACECTSSCTSKATM | |
| SCHEMBL11995841 | 0.86 | CTSS (0.53) | MMEACECTSSCTSKATM | |
| SCHEMBL18922327 | 0.84 | MME (0.46) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | disclosed |
| US-20170349574-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885CTSS 69/4885 |
| US-11634413-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885CTSS 69/4885 |
| US-20170349574-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885CTSS 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.